MedWorm: Aspirin

Warfarin Fails to Reduce Stroke in HF Patients (CME/CE)

MedPage Today State Required CME — Tue, 07 Feb 2012 16:20:45 +0100

NEW ORLEANS (MedPage Today) -- Warfarin was statistically equal to aspirin in reducing death or stroke in heart failure patients, but increased GI bleeds, a randomized trial found. (Source: MedPage Today State Required CME)

MedWorm Sponsor Message: Find the best January Sales in the UK.

New guidelines suggest DVT prophylaxis not appropriate for all patients

EurekAlert! - Medicine and Health — Tue, 07 Feb 2012 05:00:00 +0100

(American College of Chest Physicians) New evidence-based guidelines from the American College of Chest Physicians recommend considering individual patients' risk of thrombosis when deciding for or against the use of preventive therapies for deep vein thrombosis and venous thromboembolism. Furthermore, the ACCP now indicates aspirin is an option for the prevention of DVT/VTE in major orthopedic surgery. (Source: EurekAlert! - Medicine and Health)

Aspirin may prevent DVT and PE in joint replacement patients

EurekAlert! - Medicine and Health — Tue, 07 Feb 2012 05:00:00 +0100

(American Academy of Orthopaedic Surgeons) Aspirin, along with the use of stockings and a foot pump, are safe and effective therapies in preventing deep vein thrombosis and pulmonary embolism in most joint replacement patients, according to research presented today at the American Academy of Orthopaedic Surgeons 2012 Annual Meeting. Patients at high risk for DVT made require the use of anticoagulation therapies. (Source: EurekAlert! - Medicine and Health)

Aspirin Vs Warfarin Comparison for Heart Failure Treatment

Disabled World — Mon, 06 Feb 2012 15:36:50 +0100

In the largest and longest head-to-head comparison of two anti-clotting medications, warfarin was similar to aspirin in preventing deaths and strokes in patients with heart failure with normal heart rhythm. (Source: Disabled World)

In Heart Failure Treatment, Warfarin And Aspirin Are Similar

Health News from Medical News Today — Mon, 06 Feb 2012 09:00:00 +0100

In the largest and longest head-to-head comparison of two anti-clotting medications, warfarin and aspirin were similar in preventing deaths and strokes in heart failure patients with normal heart rhythm, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012. "Although there was a warfarin benefit for patients treated for four or more years, overall, warfarin and aspirin were similar," said Shunichi Homma, M.D., lead author of the study and the Margaret Milliken Hatch Professor of Medicine at Columbia University in New York... (Source: Health News from Medical News Today)

Clopidogrel With Aspirin Doesn't Prevent More Small Strokes, May Increase Risk Of Bleeding, Death

Health News from Medical News Today — Mon, 06 Feb 2012 09:00:00 +0100

The anti-blood clot regimen that adds the drug clopidogrel (Plavix) to aspirin treatment is unlikely to prevent recurrent strokes and may increase the risk of bleeding and death in patients with subcortical stroke according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012. Because of these preliminary results, researchers ended the anti-clotting part of the Secondary Prevention of Small Subcortical Strokes Trial (SPS3) in August 2011. The part of the study that examines the effect of high blood pressure treatments will continue... (Source: Health News from Medical News Today)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Erratic Heart Rhythm May Account For Some Unexplained Strokes

Health News from Medical News Today — Sat, 04 Feb 2012 08:00:00 +0100

Occasional erratic heart rhythms appear to cause about one-fifth of strokes for which a cause is not readily established, according to research presented at the American Stroke Association's International Stroke Conference 2012. About one-third of survivors leave the hospital with the cause of their stroke still undetermined. "Identifying and treating these patients for irregular rhythm could reduce the recurrence of stroke by 40 percent compared to reducing the risk by treating them with aspirin," said Daniel J. Miller, M.D... (Source: Health News from Medical News Today)

Warfarin and Aspirin Are Similar in Heart Failure Treatment

MedlinePlus Health News — Sat, 04 Feb 2012 06:09:10 +0100

Source: American Heart Association Related MedlinePlus Pages: Blood Thinners, Heart Failure (Source: MedlinePlus Health News)

Aspirin, Warfarin Fare Equally for Heart Failure Patients

The Doctors Lounge - Cardiology — Sat, 04 Feb 2012 05:00:00 +0100

Each of these anti-clotting drugs had similar effectiveness in preventing deaths, study found (Source: The Doctors Lounge - Cardiology)

Clopidogrel with Aspirin Doesn't Prevent More Small Strokes, May Increase Risk of Bleeding, Death

MedlinePlus Health News — Fri, 03 Feb 2012 23:46:52 +0100

Source: American Heart Association Related MedlinePlus Page: Stroke (Source: MedlinePlus Health News)

No recurrent stroke prevention seen with clopidogrel plus aspirin

theHeart.org — Fri, 03 Feb 2012 22:15:57 +0100

A new study shows that the combination of clopidogrel and aspirin increases risk of hemorrhage and mortality, including nonvascular mortality, vs aspirin alone. (Source: theHeart.org)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Aspirin as Effective as Warfarin in Heart Failure: WARCEFAspirin as Effective as Warfarin in Heart Failure: WARCEF

Medscape Today Headlines — Fri, 03 Feb 2012 20:47:09 +0100

Although there was an edge for warfarin for those treated for 4 or more years, there is "no compelling" reason to anticoagulate these patients, researchers say. Medscape Medical News (Source: Medscape Today Headlines)

No Stroke Prevention Benefit of Clopidogrel Plus AspirinNo Stroke Prevention Benefit of Clopidogrel Plus Aspirin

Medscape Today Headlines — Fri, 03 Feb 2012 20:02:42 +0100

A new study shows that the combination clopidogrel and aspirin increases risk of hemorrhage and mortality including non-vascular mortality vs aspirin alone. Medscape Medical News (Source: Medscape Today Headlines)

Aspirin as effective as warfarin in heart failure: WARCEF

theHeart.org — Fri, 03 Feb 2012 19:55:27 +0100

Although there was an edge for warfarin for those treated for four or more years, there is "no compelling" reason to anticoagulate these patients, researchers say. (Source: theHeart.org)

Warfarin and aspirin are similar in heart failure treatment, study suggests

ScienceDaily Headlines — Fri, 03 Feb 2012 19:14:14 +0100

Underuse of Aspirin for Primary and Secondary Prevention of Cardiovascular Disease Events in Women

Journal of Women — Fri, 03 Feb 2012 16:36:29 +0100

Journal of Women's Health , Vol. 0, No. 0. (Source: Journal of Women)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Clopidogrel with aspirin doesn't prevent more small strokes, may increase risk of bleeding and death, researchers report

ScienceDaily Headlines — Fri, 03 Feb 2012 16:33:33 +0100

Clopidogrel With Aspirin Doesn't Prevent More Small Strokes, May Increase Risk of Bleeding, Death

Medical News (via PRIMEZONE) — Fri, 03 Feb 2012 14:00:00 +0100

NEW ORLEANS, Feb. 3, 2012 (GLOBE NEWSWIRE) -- The anti-blood clot regimen that adds the drug clopidogrel (Plavix) to aspirin treatment is unlikely to prevent recurrent strokes and may increase the risk of bleeding and death in patients with subcortical stroke according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012. (Source: Medical News (via PRIMEZONE))

Warfarin and Aspirin are Similar in Heart Failure Treatment

Medical News (via PRIMEZONE) — Fri, 03 Feb 2012 14:00:00 +0100

NEW ORLEANS, Feb. 3, 2012 (GLOBE NEWSWIRE) -- In the largest and longest head-to-head comparison of two anti-clotting medications, warfarin and aspirin were similar in preventing deaths and strokes in heart failure patients with normal heart rhythm, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012. (Source: Medical News (via PRIMEZONE))

Warfarin and aspirin are similar in heart failure treatment

EurekAlert! - Medicine and Health — Fri, 03 Feb 2012 05:00:00 +0100

(American Heart Association) In the largest and longest head-to-head comparison of two anti-clotting medications, warfarin and aspirin were similar in preventing deaths and strokes in heart failure patients with normal heart rhythm, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012. (Source: EurekAlert! - Medicine and Health)

Clopidogrel with aspirin doesn't prevent more small strokes, may increase risk of bleeding, death

EurekAlert! - Medicine and Health — Fri, 03 Feb 2012 05:00:00 +0100

(American Heart Association) The anti-blood clot regimen that adds the drug clopidogrel (Plavix) to aspirin treatment is unlikely to prevent recurrent strokes and may increase the risk of bleeding and death in patients with subcortical stroke according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012. (Source: EurekAlert! - Medicine and Health)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Correction

Gut — Fri, 03 Feb 2012 05:00:00 +0100

Benamouzig R, Uzzan B, Deyra J, et al. Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. Gut 2012;61:255–61. There are two numerical errors in the last sentence of the "Results" paragraph of the Abstract of this paper. This sentence should be read as follows: "Also, the proportion of patients with at least one advanced adenoma did not differ (10/102 (10 %) in the aspirin group vs 7/83 (8.4 %) in the placebo group; NS)." (Source: Gut)

Aspirin Is Underused By Stroke Survivors

Health News from Medical News Today — Thu, 02 Feb 2012 21:00:00 +0100

NEW ORLEANS - Roughly 40% of patients who survive a stroke do not take aspirin on a daily basis, despite established guidelines that recommend its use for secondary prevention in this population, investigators announced at the 2012 International Stroke Conference. Dr. John G. Fort, Chief Medical Officer of POZEN Inc. in Chapel Hill, North Carolina, presented data from an Internet-based questionnaire that aimed to determine aspirin use in patients who had experienced a myocardial infarction (MI) or stroke... (Source: Health News from Medical News Today)

Aspirin: Subdural haematoma in an elderly patient: case report

Reactions — Thu, 02 Feb 2012 18:34:27 +0100

(Source: Reactions)

Baby Aspirin for Geriatric Patients

Consultant Live — Thu, 02 Feb 2012 12:00:00 +0100

Advice for getting aspirin into older patients (Source: Consultant Live)

Experimental Drug Might Beat Aspirin in Preventing Repeat Strokes: Study

The Doctors Lounge - Cardiology — Thu, 02 Feb 2012 05:00:00 +0100

It's not yet FDA-approved, but apixaban cut clot risk caused by abnormal heartbeat (Source: The Doctors Lounge - Cardiology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Apixaban vs. aspirin in patients with atrial fibrillation and previous stroke or TIA: subgroup analysis from AVERROES trial

NeLM - News — Thu, 02 Feb 2012 05:00:00 +0100

Source: Lancet Neurology Area: News Apixaban, reduced the risk of stroke or systemic embolism in patients with atrial fibrillation who were at high risk of stroke but unsuitable for vitamin K antagonist therapy in the AVERROES study (n= 5599). In a report in the Lancet Neurolgy, researchers evaluated whether the subgroup of patients with previous stroke or transient ischaemic attack (TIA) would show a greater benefit from apixaban compared with aspirin than patients without previous cerebrovascular events. Patients were randomised to apixaban 5mg BD or aspirin (81 to 324mg daily). The mean follow-up was 1.1 years. The primary efficacy outcome was stroke or systemic embolism; the primary safety outcome was major bleeding. This pre-specified subgroup analysis estimated compared 1...

Review of HPLC methods and HPLC methods with mass spectrometric detection for direct determination of aspirin with its metabolite(s) in various biological matrices.

Biomedical Chromatography : BMC — Thu, 02 Feb 2012 05:00:00 +0100

Authors: Mullangi R, Sharma K, Srinivas NR Abstract Aspirin, the most widely used drug in the world, has been known to mankind for over a century. It is not only the pharmacologically active entity, but is also biotransformed into a major metabolite, i.e. salicylic acid, which also exhibits similar pharmacologic/pharmacodynamic properties. Hence it is necessary to quantitate aspirin along with its metabolite(s) in various biological matrices accurately and precisely to correlate with pharmacological/pharmacodynamic activity. This paper provides a comprehensive overview of various bioanalytical methods (HPLC and LC-MS/MS) that have been reported for direct quantitation of aspirin along with its metabolite(s). The review also provides general information on sample collection, sample ...

Dabigatran for patients with a mechanical valve

Heart, Lung and Circulation — Wed, 01 Feb 2012 05:00:00 +0100

We read with great interest the case report by Stewart et al. , describing a 62 year-old Caucasian patient who suffered thrombosis of a mechanical aortic valve and an embolic stroke whilst being treated for more than eight months with dabigatran (150mg b.i.d.) and 100mg aspirin. Dabigatran etexilate is a new oral direct thrombin inhibitor currently approved for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. In the RELY study , a dose of 150mg b.i.d. was shown to be associated with a significantly lower risk of stroke and systemic embolism with a similar risk of major bleeding when compared with warfarin. (Source: Heart, Lung and Circulation)

Re: Letter responding to “Dabigatran for patients with a mechanical valve – by F. Van de Werf and J. Eikelboom”

Heart, Lung and Circulation — Wed, 01 Feb 2012 05:00:00 +0100

We thank Drs Van De Werf and Eikelboom for drawing attention to the potential for differences in renal function to influence the efficacy as well as safety of dabigatran. Our patient suffered thrombosis on a St Jude aortic valve whilst taking dabigatran 150mgbd and aspirin 100mg daily. His calculated serum creatinine clearance was 66ml/min/1.73m2, which is similar to the average creatinine clearance of patients who participated in the RELY trial . It is therefore unlikely plasma levels of dabigatran were lower than expected because of good renal function. (Source: Heart, Lung and Circulation)

EXTRA STRENGTH HEADACHE RELIEF (Acetaminophen, Aspirin And Caffeine) Tablet, Film Coated [CHAIN DRUG MARKETING ASSOCIATION INC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 01 Feb 2012 05:00:00 +0100

Updated Date: Feb 1, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

Aspirin and Angioplasty

Journal of the American College of Radiology : JACR — Wed, 01 Feb 2012 05:00:00 +0100

Every August for 30 years, the Federal Reserve Bank of Kansas City has convened a meeting in Jackson Hole, Wyoming. Attracting some of the world's best minds in finance and economics, the policy symposium covers topics such as emerging markets, economic growth, and global competiveness. (Source: Journal of the American College of Radiology : JACR)

Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: The BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design

American Heart Journal — Wed, 01 Feb 2012 05:00:00 +0100

Conclusions: This study will test the comparative long-term safety and efficacy of newest-generation stents on the background of contemporary antiplatelet therapy in a large all-comer population undergoing large native coronary artery stenting. (Source: American Heart Journal)

Rationale and design of the TAXUS Libertē Post-Approval Study: Examination of patients receiving the TAXUS Liberté stent with concomitant prasugrel therapy in routine interventional cardiology practice

American Heart Journal — Wed, 01 Feb 2012 05:00:00 +0100

Background: Observational studies of new coronary stents are necessary to assess performance in a variety of complex patient and lesion types. Furthermore, the optimal dose and duration of thienopyridine treatment is unclear, particularly in patients with complex clinical conditions. The TAXUS Libertē Post-Approval Study is designed to provide 5-year data on the TAXUS Liberté paclitaxel-eluting stent with concomitant prasugrel therapy in routine clinical practice and to contribute data to the DAPT study.Study Design: The TAXUS Libertē Post-Approval Study is a prospective, multicenter, observational study. Enrollment of approximately 4,200 patients receiving ≥1 TAXUS Liberté stents is planned. All patients without a contraindication will be prescribed prasugrel plus aspirin for 1 year...

Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy

Journal of Thrombosis and Thrombolysis — Tue, 31 Jan 2012 16:44:49 +0100

Abstract To develop an integrated metric of non-COX-1-dependent platelet function (NCDPF) to measure the temporal response to aspirin in healthy volunteers and diabetics. NCDPF on aspirin demonstrates wide variability, despite suppression of COX-1. Although a variety of NCDPF assays are available, no standard exists and their reproducibility is not established. We administered 325 mg/day aspirin to two cohorts of volunteers (HV1, n = 52, and HV2, n = 96) and diabetics (DM, n = 74) and measured NCDPF using epinephrine, collagen, and ADP aggregometry and PFA100 (collagen/epi) before (Pre), after one dose (Post), and after several weeks (Final). COX-1 activity was assessed with arachidonic acid aggregometry (AAA). The primary outcome of the s...

Perioperative Management of a Patient with Recently Placed Drug-Eluting Stents Requiring Urgent Spinal Surgery

Journal of General Internal Medicine — Tue, 31 Jan 2012 07:11:13 +0100

We report the case of a woman who required spinal surgery 3 months after she underwent placement of two drug-eluting stents. The patient’s clopidogrel was stopped 5 days prior to surgery and an infusion of eptifibatide was used to “bridge” antiplatelet therapy during the perioperative period. Postoperatively, anticoagulation therapy was reinstituted using aspirin with clopidogrel. This case serves as a successful example of bridging therapy using a short acting and gycoprotein (GP) IIb/IIIa inhibitor as a means of maintaining antiplatelet therapy during the perioperative period to minimize the risk of stent thrombosis and the risk of intraoperative bleeding. Content Type Journal ArticleCategory Clinical Practice: Clinical VignettesPages 1-4DOI 10.1007/s11606-012-1...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATEcapsule [Lannett Company, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 31 Jan 2012 05:00:00 +0100

Updated Date: Jan 31, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Is non-therapeutic aspirin use in children a problem in South Africa? - Donald K, Hall S, Seaton C, Tanyanyiwa D.

SafetyLit: All (Unduplicated) — Mon, 30 Jan 2012 15:32:08 +0100

We report on a severely ill infant who had ingested aspirin contained in a traditional medicine and review 21 other patients with pre-admission non-therapeutic sali... (Source: SafetyLit: All (Unduplicated))

Bowel cancer awareness campaign launched

OnMedica Latest News — Mon, 30 Jan 2012 05:00:00 +0100

First ever national bowel cancer campaign aims to boost early diagnosisRelated items from OnMedicaFaecal blood testing best to spot cancer and cost-effectiveNational campaign to raise patient awareness of bowel cancerBenefits of aspirin to treat bowel cancerSmoking may worsen cancer painAudit of oesophago-gastric cancer calls for better staffing (Source: OnMedica Latest News)

Coronary artery calcium testing predicts mortality in diabetes patients

MedWire News - Diabetes — Mon, 30 Jan 2012 00:00:00 +0100

Coronary artery calcium scoring can help risk stratify individuals with diabetes, and identify patients who may benefit from therapies such as low-dose aspirin, a study shows. (Source: MedWire News - Diabetes)

A new look at antiplatelet agent‐related peptic ulcer: An update of prevention and treatment

Journal of Gastroenterology and Hepatology — Sun, 29 Jan 2012 20:50:05 +0100

AbstractPatients taking antiplatelet agent for the prevention of cardiovascular diseases who develop gastrointestinal bleeding represent a serious challenge in clinical practice. The initial step in reducing gastrointestinal risk of antiplatelet therapy is to assess whether the patient has a continued need for antiplatelet therapy. The next step is to eliminate the risk factors that may place the patient at increased gastrointestinal risk. In the management of bleeding ulcer patients with high‐risk stigmata of recent hemorrhage, resuming antiplatelet agents at 3‐5 days after the last dosing is a reasonable strategy. However, patients with low‐risk stigmata can keep taking antiplatelet agents immediately following endoscopy. In the management of aspirin‐related uncomplicated peptic ...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Evaluation of onset of pain relief from micronized aspirin in a dental pain model

Inflammopharmacology — Sat, 28 Jan 2012 16:52:16 +0100

Abstract A new formulation of a micronized acetylsalicylic acid swallowable tablet with an effervescent component (FR-aspirin) was evaluated in two independent studies using the dental impaction pain model. These clinical studies were performed to confirm the results of preclinical dissolution studies and human pharmacokinetic studies, which indicated an improved onset of analgesia without compromising duration of effect or safety. Study 1 evaluated a 650-mg dose of aspirin and Study 2 evaluated a 1,000-mg dose of aspirin. Both studies were double-blinded, parallel group and compared to regular aspirin (R-aspirin) and placebo. Speed of onset was measured by the double stopwatch method for time to both first perceptible relief and meaningful relief. In both studies, the FR-...

Use of aspirin questioned as primary prevention for CVD

Drug Topics - Pharmacy News — Fri, 27 Jan 2012 05:00:00 +0100

Aspirin prophylaxis in people without prior cardiovascular disease does not appear to reduce cardiovascular death or cancer mortality, however it was associated with reductions in nonfatal myocardial infarction, according to the results of a meta-analysis published online January 9 in the Archives of Internal Medicine. (Source: Drug Topics - Pharmacy News)

BUTALBITAL, ASPIRIN AND CAFFEINEtablet [West-Ward Pharmaceutical Corp]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 27 Jan 2012 05:00:00 +0100

Updated Date: Jan 27, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Study raises questions about aspirin as primary prevention for CVD

Modern Medicine — Fri, 27 Jan 2012 00:07:57 +0100

Aspirin prophylaxis in people without prior cardiovascular disease does not appear to reduce cardiovascular death or cancer mortality, according to the results of a meta-analysis published online January 9 in the Archives of Internal Medicine. (Source: Modern Medicine)

Patient Management After Noninvasive Cardiac Imaging: Results From SPARC (Study of Myocardial Perfusion and Coronary Anatomy Imaging Roles in Coronary Artery Disease)

Journal of the American College of Cardiology — Thu, 26 Jan 2012 13:57:11 +0100

Conclusions: Overall, noninvasive testing had only a modest impact on clinical management of patients referred for clinical testing. Although post-imaging use of cardiac catheterization and medical therapy increased in proportion to the degree of abnormality findings, the frequency of catheterization and medication change suggests possible undertreatment of higher risk patients. Patients were more likely to undergo cardiac catheterization after computed tomography angiography than after single-photon emission computed tomography or positron emission tomography after normal/nonobstructive and mildly abnormal study findings. (Study of Perfusion and Anatomy's Role in Coronary Artery [CAD] [SPARC]; NCT00321399) (Source: Journal of the American College of Cardiology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Use of aspirin questioned as primary prevention for CVD

Drug Topics - Top News — Thu, 26 Jan 2012 05:00:00 +0100

When a little aspirin may be enough

Blood — Thu, 26 Jan 2012 05:00:00 +0100

(Source: Blood)

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide

Blood — Thu, 26 Jan 2012 05:00:00 +0100

This study was registered at www.clinicaltrials.gov as #NCT00551928. (Source: Blood)

Use of aspirin questioned as primary prevention for CVD

Modern Medicine — Thu, 26 Jan 2012 05:00:00 +0100

MedWorm Sponsor Message: Find the best January Sales in the UK.

Dual or Mono Antiplatelet Therapy for Patients With Acute Ischemic Stroke or Transient Ischemic Attack: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Stroke — Thu, 26 Jan 2012 05:00:00 +0100

CONCLUSIONS: Dual antiplatelet therapy appears to be safe and effective in reducing stroke recurrence and combined vascular events in patients with acute ischemic stroke or transient ischemic attack as compared with mono therapy. These results need to be tested in prospective studies. PMID: 22282894 [PubMed - as supplied by publisher] (Source: Stroke)

Cerebrolysin in Patients With Acute Ischemic Stroke in Asia: Results of a Double-Blind, Placebo-Controlled Randomized Trial.

Stroke — Thu, 26 Jan 2012 05:00:00 +0100

CONCLUSIONS: In this study, the confirmatory end point showed neutral results between the treatment groups. However, a favorable outcome trend was seen in the severely affected patients with ischemic stroke treated with Cerebrolysin. This observation should be confirmed by a further clinical trial.Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00868283. PMID: 22282884 [PubMed - as supplied by publisher] (Source: Stroke)

Teen to meet 11 strangers who saved his life by donating blood, platelets

UCLA Newsroom: Health Sciences — Wed, 25 Jan 2012 23:00:00 +0100

WHAT: Due to confidentiality laws, most blood donors never know who receives their blood. Similarly, patients never learn the identities of the people who donated their time and blood to save their lives. But a rare reunion organized by the UCLA Blood and Platelet Center will change that. A teenage boy who underwent a heart transplant at Mattel Children's Hospital UCLA will meet 11 blood and platelet donors who sustained his life with their generous donations. WHO: RECIPIENT Donovan Ho Ho, 17, of Orange, Calif., will express his gratitude for the 72 units of donated blood, plasma and platelets that helped make his 2010 organ transplant successful after his heart failed. Accompanied by his 10-year-old brother, parents, grandparents and great-grandmo...

Management of Myeloproliferative Neoplasms: From Academic Guidelines to Clinical Practice

Current Hematologic Malignancy Reports — Wed, 25 Jan 2012 18:05:35 +0100

Abstract Myeloproliferative neoplasms (MPNs) are clonal disorders characterized by excessive production of mature cells. In most of the classic Philadelphia-negative MPNs—polycythemia vera (PV), essential thrombocythemia (ET), and MPN-associated myelofibrosis (MPN-MF)—oncogenic mutations affecting JAK2 or MPL lead to constitutive activation of cytokine-regulated intracellular signalling pathways. The traditional therapy for PV and ET is the prevention of thrombotic events with antiproliferative agents in association with aspirin. New drugs such as pegylated interferon and anti-JAK agents are candidates for slowing the evolution to myelofibrosis or leukemia. Conventional therapy for MPN-MF is driven by clinical needs, primarily anemia and splenomegaly. Lenalidomide and ...

Obstetric complications and pregnancy-related venous thromboembolism: the effect of low molecular weight heparin on their prevention in carriers of factor V leiden or prothrombin G20210A mutation.

Thrombosis and Haemostasis — Wed, 25 Jan 2012 05:00:00 +0100

Authors: Tormene D, Grandone E, De Stefano V, Tosetto A, Palareti G, Margaglione M, Castaman G, Rossi E, Ciminello A, Valdrè L, Legnani C, Tiscia GL, Bafunno V, Carraro S, Rodeghiero F, Simioni P Abstract Whether the administration of low-molecular-weight heparin (LMWH) during pregnancy is effective in preventing obstetric complications and pregnancy-related venous thromboembolism (VTE) in women who are carriers of factor V Leiden (FVL) and/or prothrombin variant G20210A (PTm) is controversial. This observational study investigated the possible efficacy of pharmacological treatment with LMWH ± aspirin (ASA) in pregnancy outcomes in 1,011 pregnancies of 416 women with thrombophilia (FVL and/or PTm). Most patients were chosen on the basis of previous obstetrical complications (36%)...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

PHYSICIANSCARE NON ASPIRIN EXTRA STRENGTH (Acetaminophen) Tablet, Film Coated [Acme United Corporation]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 24 Jan 2012 05:00:00 +0100

Updated Date: Jan 24, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Use of global coronary heart disease risk assessment in practice: a cross-sectional survey of a sample of U.S. physicians

BMC Health Services Research — Tue, 24 Jan 2012 05:00:00 +0100

Conclusions: Reported awareness of tools to calculate global CHD risk appears high, but the majority of physicians in this sample do not use CHD risk assessments in practice. A minority of physicians in this sample use global CHD risk to guide prescription decisions or to motivate patients. Educational interventions and system improvements to improve physicians' effective use of global CHD risk assessment should be developed and tested. (Source: BMC Health Services Research)

Postmenopausal Women with Constipation and Cardiovascular Disease

The American Journal of Medicine — Mon, 23 Jan 2012 23:45:01 +0100

This study clearly documents the distribution of the many cardiovascular risk factors, such as smoking and diabetes. Although the study does document the use of symptomatic medications such as diuretics and calcium channel blockers, it would be helpful to know the distribution of mortality-reducing medications in post-cardiovascular injury, such as angiotensin-converting enzyme inhibitors, beta-blockers, and aspirin. (Source: The American Journal of Medicine)

The Reply

The American Journal of Medicine — Mon, 23 Jan 2012 23:45:01 +0100

We would like to thank Salamon et al for their interest in our article. They raise 2 very interesting points. The first is the distribution of medications known to affect cardiovascular mortality, such as statins, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and aspirin in our study population, and the possible impact that these variables might have on our results when included in the multivariate analysis. The distributions of baseline use of ACE inhibitors, beta-blockers, aspirin, and statins by constipation category are shown in the . The prevalence of use of these medications was slightly higher with more severe constipation, although this may be due to age—because both constipation severity and medication use increase with age. Overall, the prevalence of statin use...

Aspirin and the Harmful Effect of NSAIDs

The American Journal of Medicine — Mon, 23 Jan 2012 23:45:01 +0100

The article by Bavry et al reporting the recurrence of myocardial infarction after the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with established cardiovascular disease is of great interest and of relevance for clinicians working in the “real world.” Although the mechanism for the harmful effect of NSAIDs remains poorly understood, it is feasible that NSAIDs would induce an imbalance between cyclooxygenase-2 (COX-2)-derived prostacyclin (PGI2) and the COX-1-derived thromboxane (TXA2). COX-2 inhibitors do not affect TXA2 level, may increase platelets reactivity, and could exert prothrombotic effects. Aspirin decreases both COX-1-derived TXA2 and PGI2, preventing the imbalance of these 2 prostanoids. In the Bavry et al study, it is possible to suppose that some pat...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Systematic Reporting Bias in Meta-analyses of Trials of Aspirin for the Primary Prevention of Cardiovascular Disease

The American Journal of Medicine — Mon, 23 Jan 2012 23:45:01 +0100

I read with interest the meta-analysis of trials of aspirin for the primary prevention of cardiovascular disease. After almost 1 million person-years' follow-up, >3500 deaths, and almost 4000 cardiovascular events, treatment with aspirin might have prevented 21 deaths, possibly none cardiovascular, 88 myocardial infarctions, and 13 strokes, and may have caused 387 major gastrointestinal hemorrhages. Incredibly, the authors believe this analysis should persuade people to take, rather than avoid, aspirin. If the data on mortality were true, that might just be justified. However, confidence intervals barely exclude the null effect. (Source: The American Journal of Medicine)

Aspirin not worth risks for primary CVD prevention

Reactions — Mon, 23 Jan 2012 18:35:21 +0100

(Source: Reactions)

Reversal of the anti‐platelet effects of aspirin and clopidogrel

Journal of Thrombosis and Haemostasis — Mon, 23 Jan 2012 05:00:00 +0100

Conclusions: Platelet aggregation recovers within 4 days of stopping aspirin but clopidogrel must be stopped for 10 days to achieve a normal aggregatory response. (Source: Journal of Thrombosis and Haemostasis)

High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events

Evidence-Based Medicine — Mon, 23 Jan 2012 05:00:00 +0100

Context In the current era, periprocedural myocardial infarction (MI) can still occur in a significant proportion of percutaneous coronary interventions (PCIs).1 Large periprocedural ischaemic events are associated with harm; however, even small increases in cardiac enzymes have been associated with increased long-term mortality.2 Attempts to enhance the safety of PCI have typically occurred through the use of potent antiplatelet agents (eg, aspirin, ADP receptor blockers (clopidogrel and prasugrel) and glycoprotein inhibitors (abciximab and eptifibatide)), as well as antithrombin agents (eg, unfractionated heparin, low-molecular weight heparin and bivalirudin). Although antiplatelet and antithrombin agents are effective at reducing ischaemic events, a cost from their use is sometimes paid...

Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events

Evidence-Based Medicine — Mon, 23 Jan 2012 05:00:00 +0100

Context Proton pump inhibitors (PPIs) block the final step in gastric acid production, increasing intragastric pH from about 1 to above 4, depending on the agent and dose used.1 This increase may influence the fate of drugs in the stomach. In the case of acetylsalicylic acid (ASA), neutralisation of gastric contents significantly decreases the absorption of both ASA and salicylic acid,2 but the clinical significance of this is uncertain. While lansoprazole does not influence the effect of low-dose enteric-coated ASA on platelet aggregation,3 patients with coronary disease receiving PPIs appear to have an impaired platelet response to aspirin.4 Methods To explore the consequences of the potential drug interaction between PPIs and ASA, Charlot et al conducted a cohort study of 19 925 patient...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Aspirin use and bleeding risk after endoscopic submucosal dissection in patients with gastric neoplasms

Endoscopy — Mon, 23 Jan 2012 05:00:00 +0100

Conclusions: Continuous aspirin use increases the risk of bleeding after gastric ESD. Aspirin use should be stopped in patients with a low risk for thromboembolic disease to minimize bleeding complications.[...]© Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals:Table of contents | Abstract | Full text (Source: Endoscopy)

Japanese case of Budd‐Chiari syndrome due to hepatic vein thrombosis successfully treated with liver transplantation

Hepatology Research — Sat, 21 Jan 2012 22:48:33 +0100

A 22‐year‐old Japanese woman was found to have severe esophageal varices and then suffered from hepatic encephalopathy. She was diagnosed with Budd‐Chiari syndrome (BCS) due to hepatic vein (HV) thrombosis accompanied by portal vein thrombosis without inferior vena cava (IVC) obstruction. Latent myeloproliferative neoplasm (MPN) lacking the JAK2‐V617F mutation was considered to be the underlying disease. Liver transplantation was strikingly effective for treating the clinical symptoms attributable to portal hypertension. Although thrombosis of the internal jugular vein occurred due to thrombocythemia, which manifested after transplantation despite anticoagulation therapy with warfarin, the thrombus immediately disappeared with the addition of aspirin. Neither thrombosis nor BCS has...

Aspirin - Ability To Prevent Cervical Cancer In HIV Infected Women

Health News from Medical News Today — Fri, 20 Jan 2012 16:00:00 +0100

According to a study published in the current issue of the journal Cancer Prevention Research, aspirin should be assessed for its ability to prevent cervical cancer developing in women infected with HIV. Aspirin has the potential to provide considerable benefit for women in Africa, the Caribbean and Latin America, regions where death rates from cervical cancer are extremely high. The study was conducted by global health investigators at New York-Presbyterian Hospital/Weill Cornell Medical Center and cancer specialists in New York, Haiti and Qatar... (Source: Health News from Medical News Today)

Aspirin Merits Testing For Prevention Of Cervical Cancer In HIV-Infected Women

Health News from Medical News Today — Fri, 20 Jan 2012 09:00:00 +0100

Research conducted by NewYork-Presbyterian Hospital/Weill Cornell Medical Center global health investigators and cancer specialists in New York, Qatar and Haiti suggests that aspirin should be evaluated for its ability to prevent development of cervical cancer in HIV-infected women. The report, published in the current issue of journal Cancer Prevention Research, says this simple and inexpensive solution has the potential to provide enormous benefit for women in the Caribbean, Latin America and Africa, who suffer from a disproportionately high rate of cervical cancer death... (Source: Health News from Medical News Today)

DCBLD2 Gene Variations Correlate with Nasal Polyposis in Korean Asthma Patients

Lung — Fri, 20 Jan 2012 07:47:07 +0100

Conclusions Although further replication and validation are needed, these findings suggest that DCBLD2 could be a potential marker and drug target for treatment of nasal polyposis in Korean asthma patients. Content Type Journal ArticlePages 1-9DOI 10.1007/s00408-011-9354-8Authors Charisse Flerida A. Pasaje, Department of Life Science, Sogang University, Seoul, 121-742 Republic of KoreaJoon Seol Bae, Department of Life Science, Sogang University, Seoul, 121-742 Republic of KoreaByung-Lae Park, Department of Genetic Epidemiology, SNP Genetics, Inc., Seoul, 153-803 Republic of KoreaHyun Sub Cheong, Department of Genetic Epidemiology, SNP Genetics, Inc., Seoul, 153-803 Republic of KoreaJeong-Hyun Kim, Department of Life Science, Sogang University, Seoul, 121-742 Republic ...

MedWorm Sponsor Message: Find the best January Sales in the UK.

High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype

Heart — Fri, 20 Jan 2012 05:00:00 +0100

To the Editor The study performed by Breet et al1 supported our previous suggestion that a cut-off of >550 aspirin reaction units (ARU) was too high to identify high on-treatment platelet reactivity (HPR).2 The cut-off defined by the highest quartile (461 ARU) from our study2 is remarkably similar to the 454 ARU cut-off value associated with 1-year outcomes in the Breet et al study.1 Moreover, across ARU quartiles, reactivity to ADP and collagen significantly increased.2 In a new analysis of 558 patients undergoing elective percutaneous coronary intervention during aspirin and clopidogrel treatment, we observed that aggregations induced by 5 μM ADP and 0.5 mg/ml arachidonic acid (AA) correlated well (r=0.625), as measured by light transmittance aggregometry (...

The Authors' reply

Heart — Fri, 20 Jan 2012 05:00:00 +0100

We thank Dr Jeong and colleagues for their comments1 regarding the incidence of dual high on-treatment platelet reactivity in patients undergoing elective percutaneous coronary intervention and its impact on clinical outcome.2 They raise several important issues. First, they provide additional information on the optimal cut-off value of the VerifyNow platelet function test to detect high on-aspirin platelet reactivity. Due to a lack of consensus on the optimal method to quantify high on-aspirin platelet reactivity and on the cut-off value associated with clinical risk, the measurement of platelet reactivity has not been widely implemented and included in the guidelines. Furthermore, the correlation between platelet function tests is moderate and the different tests identify other patients...

PHYSICIANSCARE NON ASPIRIN EXTRA STRENGTH (Acetaminophen) Tablet, Film Coated [Acme United Corporation]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 20 Jan 2012 05:00:00 +0100

Updated Date: Jan 20, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

The Cough Receptor TRPV1 Agonists 15(S)-HETE and LTB4 in the Cough Response to Hypertonicity.

Inflammation and Allergy Drug Targets — Fri, 20 Jan 2012 05:00:00 +0100

Authors: Koskela H, Purokivi M, Nieminen R, Moilanen E Abstract Asthmatic patients are hypersensitive to the cough-provoking effect of hypertonic aerosols. 15-hydroxyeicosatetraenoic acid (15(S)-HETE) and leukotriene (LT) B4 are asthma-related mediators which can be released upon hypertonic stimuli, and both are potent agonists of the transient receptor potential vanilloid subfamily member 1 (TRPV1), a major cough receptor. Therefore, they are potential mediators for hypertonicity-provoked cough. Twenty-six asthmatic and ten healthy subjects underwent a hypertonic saline cough provocation test. Exhaled breath condensate was collected before and after the test, and the concentrations of 15(S)-HETE and LTB4 were analysed. Neither the baseline concentrations of these mediators nor the...

Current Evidence for Antithrombotic Therapy after Peripheral Vascular Interventions.

Current Vascular Pharmacology — Fri, 20 Jan 2012 05:00:00 +0100

Authors: Saha SP, Whayne TF, Mukherjee D Abstract There is occurring a progressive increase in peripheral arterial disease (PAD) in the United States and around the World. This is undoubtedly associated with deterioration in health status and an increase in cardiovascular risk factors. There are multiple old and new antithrombotic and anticoagulation medications that have been used for the treatment of PAD. Several are considered in this review. The purpose of antithrombotics in surgery is the prevention of thrombosis of surgical bypass grafts in order to help maintain their patency. Multiple different medication approaches can be made in association with surgery. Just as in the case of peripheral vascular surgery, thrombosis also plagues the long-term maintenance of patency follow...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Trends in isolated coronary artery bypass grafting: An analysis of the Society of Thoracic Surgeons adult cardiac surgery database

The Journal of Thoracic and Cardiovascular Surgery — Thu, 19 Jan 2012 09:10:16 +0100

Conclusions: Over the past decade, the risk profile of patients undergoing CABG has changed, with fewer smokers, more diabetic patients, and better medical therapy characterizing patients referred for surgical coronary revascularization. The left internal thoracic artery is nearly universally used and outcomes have improved substantially, with a significant decline in postoperative mortality and morbidity. (Source: The Journal of Thoracic and Cardiovascular Surgery)

The Effectiveness of Implementing an Electronic Health Record on Diabetes Care and Outcomes

Health Services Research — Wed, 18 Jan 2012 15:46:45 +0100

ConclusionImplementation of a commercially available EHR in primary care practice may improve diabetes care and clinical outcomes. (Source: Health Services Research)

Microwave-assisted synthesis, pharmacological evaluation, and QSAR studies of 1,3-diaryl-2-propen-1-ones

Medicinal Chemistry Research — Wed, 18 Jan 2012 06:49:45 +0100

Abstract A series of 1,3-diaryl-2-propen-1-ones was synthesized by both the conventional and microwave irradiation methods. It was observed that a microwave-assisted method was a convenient, rapid, and high yielding method for the synthesis of 1,3-diaryl-2-propen-1-ones as compared to the conventional method. In vivo acute toxicity studies and analgesic and anti-inflammatory activities of these compounds were also evaluated. The analgesic activity was evaluated using acetic acid-induced writhing method in mice and aspirin as the standard. The anti-inflammatory activity was evaluated using carrageenan-induced rat paw edema method and indomethacin as the standard. The quantitative structure–activity relationships (QSAR) studies were carried out by correlating, individually,...

Aspirin merits testing for prevention of cervical cancer in HIV-infected women

EurekAlert! - Medicine and Health — Wed, 18 Jan 2012 05:00:00 +0100

(New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College) Research conducted by NewYork-Presbyterian Hospital/Weill Cornell Medical Center global health investigators and cancer specialists in New York, Qatar and Haiti suggests that aspirin should be evaluated for its ability to prevent development of cervical cancer in HIV-infected women. (Source: EurekAlert! - Medicine and Health)

Bleeding Risk in Randomized Controlled Trials Comparing Warfarin and Aspirin: a Systematic Review and Meta‐Analysis

Journal of Thrombosis and Haemostasis — Wed, 18 Jan 2012 05:00:00 +0100

Conclusions: This meta‐analysis failed to find a statistically significant difference in major bleeding between warfarin, target INR 2.0 to 3.5, and ASA, 50 to 650 mg daily. The trend towards increased bleeding with warfarin appears to be explained by an excess of intracranial bleeding in warfarin patients. (Source: Journal of Thrombosis and Haemostasis)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Aspirin: Urticaria during desensitisation therapy: case report

Reactions — Tue, 17 Jan 2012 19:08:18 +0100

(Source: Reactions)

Contribution of the OBSCN Nonsynonymous Variants to Aspirin Exacerbated Respiratory Disease Susceptibility in Korean Population

DNA and Cell Biology — Tue, 17 Jan 2012 15:25:07 +0100

DNA and Cell Biology , Vol. 0, No. 0. (Source: DNA and Cell Biology)

Clinician Update: Antiplatelet therapy and proton pump inhibition

NeLM - News — Tue, 17 Jan 2012 05:00:00 +0100

Source: Circulation Area: News This clinician update article discusses the use of proton pump inhibitors (PPIs) with antiplatelet therapy, illustrated with a case example. The following issues are discussed: . Risk of gastro-intestinal (GI) bleeding with antiplatelet therapy and effect of gastroprotective strategies . PPIs and aspirin interaction . PPIs and clopidogrel: Evidence for and against a clinically significant interaction . Strategies to avoid the effects of an interaction The authors conclude that the totality of evidence to date does not support a clinically significant impact of any pharmacokinetic or pharmacodynamic interactions between PPIs and the current widely used antiplatelets. They call for further evidence fr...

Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction

Arthritis Research and Therapy — Tue, 17 Jan 2012 05:00:00 +0100

IntroductionPatients with a history of myocardial infarction (MI) are often at risk for complications, including subsequent MI and death. Use of prognostic markers may aid in preventing these poor outcomes. Hyperuricemia is associated with increased risk for coronary heart disease (CHD) and/or mortality; however, it is unknown if serum urate (sUA) levels predict outcomes in patients with previous MI. The purpose of this study was to assess hyperuricemia as a biomarker of CHD outcomes in such patients. Methods: These were post hoc analyses of datasets from the Aspirin Myocardial Infarction Study, a 1:1 randomized, double-blind clinical trial, conducted from 1975 to 1979, that examined mortality rates following daily aspirin administration over 3 years in individuals with documented MI. The ...

Apixaban: A New Player in the Anticoagulant Class.

Current Drug Targets — Tue, 17 Jan 2012 05:00:00 +0100

Authors: Agrawal R, Jain P, Dikshit SN Abstract Apixaban (BMS-562247-01) is a compound being investigated as an anticoagulant. Apixaban molecule is developed in a joint venture by Pfizer and Bristol-Myers Squibb. Apixaban, a coagulation factor Xa inhibitor, approved in the E.U. in 2011 for the prevention of venous thromboembolic events in adult patients, who have undergone elective hip or knee replacement. The Apixaban based drug will be marketed under the brand name Eliquis® and is expected to rack up annual sales of over $2.5 billion. Apixaban is expected to provide stiff competition to warfarin, a popular blood thinner used in Europe. Warfarin is known to cause some serious side effects in patients. Apixaban, as compared with aspirin, reduced the risk of stroke or systemic embo...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke: a 10-year follow-up study

European Journal of Heart Failure — Tue, 17 Jan 2012 05:00:00 +0100

Conclusions In patients with HF, stroke aetiology is influenced by the presence of AF and the underlying cause of HF. Early and late stroke outcome is associated with HF severity but not with the presence of AF. (Source: European Journal of Heart Failure)

The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus

Journal of Thrombosis and Haemostasis — Tue, 17 Jan 2012 05:00:00 +0100

Conclusions: DM2 patients with inadequate glycemic control (HbA1c>53mmol/mol) have higher baseline platelet activity and incomplete suppression of platelet activity with 30 mg of aspirin. However, 100 mg of aspirin leads to optimal inhibition irrespective of glycemic control, and 300 mg does not further improve platelet suppression. (Source: Journal of Thrombosis and Haemostasis)

Well: Daily Aspirin Is Not for Everyone, Study Suggests

NYT Health — Mon, 16 Jan 2012 21:36:08 +0100

Nearly a third of middle-aged Americans regularly take aspirin in the hope of preventing a heart attack or a stroke, but in some patients this so-called wonder drug is doing more harm than good. (Source: NYT Health)

An aspirin a day may not keep the doctor away

Telegraph Health — Mon, 16 Jan 2012 07:30:34 +0100

Experts have revised their views on aspirin, salt and breast cancer - but are they right, asks James Le Fanu. (Source: Telegraph Health)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Antiplatelet resistance linked to silent cerebral emboli after coronary angiography

Modern Medicine — Mon, 16 Jan 2012 05:00:00 +0100

NEW YORK (Reuters Health) - Silent embolic cerebral infarctions occur in about one in six patients after undergoing coronary angiography, and the risk is related to the degree of platelet inhibition with aspirin and clopidogrel, a Korean study shows. (Source: Modern Medicine)

Differences in Major Bleeding Events in Elderly Surgical Patients Receiving Low Molecular Weight Heparin (LMWH) Versus LLow-dose Unfractionated Heparin (LDUH)

Journal of Surgical Research — Sat, 14 Jan 2012 22:29:59 +0100

Conclusions: Our study failed to demonstrate a significant difference in major bleeding between LMWH and UFH in surgical patients age 65 years or older. 21.1% of patients on LMWH experienced a major bleed versus 9.5% on SQH, however this was not significant . the use of Plavix, low preoperative and postoperative Hgb and HCT and low postoperative platelets were associated with higher transfusion rates. (Source: Journal of Surgical Research)

Aspirin may be too risky for blanket primary prevention

OnMedica Latest News — Sat, 14 Jan 2012 05:00:00 +0100

Study casts doubts over benefits of aspirin for primary prevention of CVDRelated items from OnMedicaAspirin for all over 45s?A daily dose of aspirin lowers cancer riskAspirin more than halves hereditary bowel cancer riskShould we reconsider aspirin? (Source: OnMedica Latest News)

Analgesic activity and safety of ash of silver used in Indian system of medicine in mice: A reverse pharmacological study

Indian Journal of Pharmacology — Sat, 14 Jan 2012 05:00:00 +0100

Conclusion: Test drug exhibited moderate analgesic activity at 50 mg/kg p.o against all type of noxious stimuli, also suggesting a role of opioidergic system. The ash of silver was been found to be safe upto a dose of 1.5 g/kg p.o. in mice without any untoward toxicity. Further studies are required to explore the effect of ash of silver on pain mediators and excitatory neurotransmitters like glutamate, aspartate, or N-methyl-D-aspartic acid (NMDA). (Source: Indian Journal of Pharmacology)

Impact of Platelet Reactivity to Adenosine Diphosphate Before Implantation of Drug-Eluting Stents on Subsequent Adverse Cardiac Events in Patients With Stable Angina.

Circulation Journal — Sat, 14 Jan 2012 05:00:00 +0100

Conclusions: These data suggested that high on-treatment platelet reactivity to ADP and subsequent occurrence of adverse ischemic events (particularly TLR) were correlated in patients with stable angina who underwent DES implantation. PMID: 22246441 [PubMed - as supplied by publisher] (Source: Circulation Journal)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Aspirin overdose: Various toxicities: 2 case reports

Reactions — Fri, 13 Jan 2012 23:22:43 +0100

(Source: Reactions)

Aspirin/clopidogrel/low molecular weight heparin: Intramuscular haematoma in an elderly patient: case report

Reactions — Fri, 13 Jan 2012 23:22:43 +0100

(Source: Reactions)

Aspirin/prasugrel: Oesophageal mucosal lesion: case report

Reactions — Fri, 13 Jan 2012 23:22:43 +0100

(Source: Reactions)

More evidence that shows aspirin risk outweighs benefits

MedWire News - Cardiology — Fri, 13 Jan 2012 14:04:51 +0100

A meta-analysis has shown that the cardiovascular benefit of routine aspirin use is offset by an increased risk for bleeding in patients with no prior cardiovascular disease. (Source: MedWire News - Cardiology)

Aspirin Therapy for Heart Disease, Stroke Prevention Not for Everyone

MedicineNet Senior Health General — Fri, 13 Jan 2012 07:00:00 +0100

Title: Aspirin Therapy for Heart Disease, Stroke Prevention Not for EveryoneCategory: Health NewsCreated: 1/13/2012 11:01:00 AMLast Editorial Review: 1/13/2012 (Source: MedicineNet Senior Health General)

MedWorm Sponsor Message: Find the best January Sales in the UK.

EXTRA STRENGTH HEADACHE RELIEF (Acetaminophen, Aspirin And Caffeine) Tablet, Film Coated [CHAIN DRUG MARKETING ASSOCIATION INC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 13 Jan 2012 05:00:00 +0100

Updated Date: Jan 13, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

EXTRA STRENGTH HEADACHE RELIEF (Acetaminophen, Aspirin And Caffeine) Tablet, Film Coated [DOLGENCORP, LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 13 Jan 2012 05:00:00 +0100

Updated Date: Jan 13, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Aspirin Therapy for Heart Disease, Stroke Prevention Not for Everyone

WebMD Health — Thu, 12 Jan 2012 22:53:12 +0100

Many people who have never had a heart attack or stroke take an aspirin every day to lower their risk for these events. While some may benefit, for many others the benefits appear to be outweighed by an increased risk for potentially serious and even life-threatening bleeding, a new study shows. (Source: WebMD Health)

When Heroin Was Available to Housewives and Aspirin Was Bad for the Heart

Psychology Today Addiction Center — Thu, 12 Jan 2012 06:13:51 +0100

It was quite a year for organic chemistry, 1898, as the acetylation of salicylic acid and morphine produced the respective drugs, aspirin and heroin. These went on to have a huge impact on the next hundred years, with aspirin becoming the most popular legal drug in history, and heroin the most popular illegal drug in history.read more (Source: Psychology Today Addiction Center)

EXTRA STRENGTH HEADACHE RELIEF (Acetaminophen, Aspirin And Caffeine) Tablet, Film Coated [WOONSOCKET PRESCRIPTION CENTER,INCORPORATED]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 12 Jan 2012 05:00:00 +0100

Updated Date: Jan 12, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

A New Era of Antithrombotic Therapy in Patients With Atrial Fibrillation.

The American Journal of the Medical Sciences — Thu, 12 Jan 2012 05:00:00 +0100

This article will review 3 new antithrombotic medications that may potentially become the mainstay for treatment of patients with atrial fibrillation in the near future. PMID: 22245946 [PubMed - as supplied by publisher] (Source: The American Journal of the Medical Sciences)

Isolation and study of insulin activated nitric oxide synthase inhibitory protein in acute myocardial infarction subjects

Journal of Thrombosis and Thrombolysis — Wed, 11 Jan 2012 17:54:24 +0100

Abstract Insulin inhibits platelet aggregation through nitric oxide synthesis by stimulating platelet insulin activated nitric oxide synthase. Impaired platelet insulin activated nitric oxide synthase in acute myocardial infarction (AMI) patients had been reported and thus our aim was to identify and isolate the factors impairing insulin activated nitric oxide in acute myocardial infarction patients’ plasma and study its effect on platelets aggregation in vitro. The insulin activated nitric oxide synthase inhibitor was identified as a protein and was purified from the plasma of AMI subjects using DEAE cellulose and Sephadex G-50 column, molecular weight determined by SDS-PAGE, nitric oxide quantified by methaemoglobin method, inhibitor protein quantified in plasma by imm...

New Aspirin Concern

MedlinePlus Health News — Wed, 11 Jan 2012 14:54:52 +0100

Source: HealthDay - Related MedlinePlus Pages: Macular Degeneration, Pain Relievers (Source: MedlinePlus Health News)

Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study

Thrombosis Journal — Wed, 11 Jan 2012 05:00:00 +0100

Conclusion: In patients treated with dual aspirin/clopidogrel therapy, nuisance and internal bleeding were significantly associated with template BT and with IPAmax in response to ADP 2 mumol/L but not in response to ADP 4 umol/L or 8 umol/L. (Source: Thrombosis Journal)

Towards evidence based medicine for paediatricians

Archives of Disease in Childhood — Wed, 11 Jan 2012 05:00:00 +0100

Archimedes seeks to assist practising clinicians by providing ‘evidence-based’ answers to common questions that are not at the forefront of research but are at the core of practice (format adapted from BestBETS published in the Emergency Medicine Journal). A full description of the format is available online at http://bit.ly/ArchiTemplate. Readers wishing to submit their own questions – with best evidence answers – are encouraged to review those already proposed at http://www.bestbets.org. If your question still hasn't been answered, feel free to submit your summary according to the instructions for authors at http://bit.ly/ArchiInstructions. Slice, dice and eventually something will happen Did you know that aspirin following myocardial infarction (MI) doesn't work ...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Healthy people should not take aspirin to prevent heart attacks

NHS Networks — Wed, 11 Jan 2012 05:00:00 +0100

Sotiris Antoniou, Royal Pharmaceutical Society spokesperson on cardiovascular medicines said: “This research confirms what pharmacists know already; that when assessing the appropriateness of aspirin for preventing heart attacks or strokes you need to assess the benefits and the risks of the individual person." (Source: NHS Networks)

Aspirin not likely to extend life in people without heart disease

Health Facts and Fears — Wed, 11 Jan 2012 05:00:00 +0100

A regular, low dose of aspirin has long been thought to be an effective preventive measure against heart attack and stroke, but a large new analysis of data from several clinical trials suggests that reductions in mortality extend only to people with a history of cardiovascular disease. (Source: Health Facts and Fears)

Resolvin D1 prevents TNF-α-mediated disruption of salivary epithelial formation.

Am J Physiol Cell Ph... — Wed, 11 Jan 2012 05:00:00 +0100

Authors: Odusanwo O, Chinthamani S, McCall A, Duffey ME, Baker OJ Abstract Sjögren's Syndrome (SS) is a chronic autoimmune disorder characterized by inflammation of salivary glands resulting in impaired secretory function. SS pathophysiology includes elevated levels of pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-18 (IL-18) and interleukin-12 (IL-12). Our recent studies indicate that chronic exposure of salivary epithelium to TNF-α and/or IFN-γ alters tight junction (TJ) integrity, leading to secretory dysfunction. Resolvins of the D-series (RvD) are endogenous lipid mediators derived from DHA that regulate excessive inflammatory responses leading to resolution and tissu...

Aspirin in Primary CVD Prevention: Risks Outweigh Benefits for MostAspirin in Primary CVD Prevention: Risks Outweigh Benefits for Most

Medscape Today Headlines — Tue, 10 Jan 2012 19:50:31 +0100

Heartwire (Source: Medscape Today Headlines)

Aspirin in primary prevention: New meta-analysis finds bleeding outweighs benefits for most

theHeart.org — Tue, 10 Jan 2012 19:00:46 +0100

But there may be a case for aspirin treatment in certain individuals at high risk of heart disease or with a family history of cancer. (Source: theHeart.org)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Routine Aspirin More Likely To Harm Than Benefit Healthy People

Health News from Medical News Today — Tue, 10 Jan 2012 19:00:00 +0100

Taking a regular dose of aspirin is more likely to harm than benefit healthy people with no history of cardiovascular diseases, such as heart attack or stroke, given the risk of internal bleeding that arises from such routine use of the drug, according to a UK-led study published online in the Archives of Internal Medicine on Monday... (Source: Health News from Medical News Today)

Heart attack risk 'rises after bereavement'

NHS News Feed — Tue, 10 Jan 2012 17:30:00 +0100

Conclusion This study looked at whether there was an association between a recent bereavement and risk of a heart attack in 1,985 older people. The study had an unusual design. Researchers asked individuals about their bereavement status shortly before a heart attack, and compared this to their status several months before. The researchers calculated that in the 24 hours after a bereavement, the participants had a 21-fold increase in the risk of having a heart attack. The risk then steadily declined after this time. A key point to consider when viewing these results is that the study looked at the circumstances of people who had had a heart attack, and not the absolute risk of having a heart attack in a group of people who had been bereaved. Therefore, it cannot directly tell us how likely...

Aspirin therapy: Study raises safety issues

Health News: CBSNews.com — Tue, 10 Jan 2012 13:48:19 +0100

Dr. John LaPook discusses the risks vs. the benefits of therapy; and also, another study on potential side effects of statins (Source: Health News: CBSNews.com)

AUDIO: 'Alternate day' aspirin recommended

BBC News | Health | UK Edition — Tue, 10 Jan 2012 07:48:03 +0100

New research suggests that taking an aspirin every day, which is commonly thought to reduce the risk of heart attacks, could be doing more harm than good. Professor Kausik Ray explains. (Source: BBC News | Health | UK Edition)

Low-Dose Aspirin to Prevent First Heart Attack or Stroke? Not So Fast

MedicineNet Cancer General — Tue, 10 Jan 2012 07:00:00 +0100

Title: Low-Dose Aspirin to Prevent First Heart Attack or Stroke? Not So FastCategory: Health NewsCreated: 1/9/2012 6:06:00 PMLast Editorial Review: 1/10/2012 (Source: MedicineNet Cancer General)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation.

Netherlands Heart Journal — Tue, 10 Jan 2012 05:00:00 +0100

CONCLUSION: Device closure of the LAA may provide an alternative strategy to chronic coumadin therapy in patients with AF and high risk of stroke and/or bleeding complications using coumadin. PMID: 22231152 [PubMed - as supplied by publisher] (Source: Netherlands Heart Journal)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Low-Dose Aspirin to Prevent First Heart Attack or Stroke? Not So Fast

The Doctors Lounge - Oncology — Mon, 09 Jan 2012 23:00:00 +0100

Modest benefits might not outweigh bleeding risk, evidence review suggests (Source: The Doctors Lounge - Oncology)

Routine aspirin 'may cause harm'

BBC News | Health | UK Edition — Mon, 09 Jan 2012 22:04:04 +0100

Healthy people who take aspirin to prevent a heart attack or stroke could be doing more harm than good, warn researchers. (Source: BBC News | Health | UK Edition)

Low-Dose Aspirin to Prevent First Heart Attack or Stroke? Not So Fast

MedlinePlus Health News — Mon, 09 Jan 2012 22:00:00 +0100

Modest benefits might not outweigh bleeding risk, evidence review suggests Source: HealthDay Related MedlinePlus Pages: Heart Attack, Pain Relievers, Stroke (Source: MedlinePlus Health News)

Aspirin guidelines need overhaul, researchers say

Reuters: Health — Mon, 09 Jan 2012 21:15:44 +0100

NEW YORK (Reuters Health) - Healthy people shouldn't be taking aspirin to prevent heart disease, researchers say in a new report that casts doubt on recommendations from U.S. health officials. (Source: Reuters: Health)

Aspirin risk

BHF National News — Mon, 09 Jan 2012 12:00:00 +0100

If you don’t have a history of heart disease you’re unlikely to benefit from regularly taking aspirin (Source: BHF National News)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

The Pattern of Platelet Response to Clopidogrel in Iranian Patients After Percutaneous Coronary Intervention.

The Journal of Clinical Pharmacology — Mon, 09 Jan 2012 05:00:00 +0100

In this study, the authors investigated the response to clopidogrel in Iranian patients after PCI. Patients who were candidates for elective PCI were enrolled in this study. All patients had received aspirin 80 to 325 mg daily for ≥1 week before PCI. Blood samples were taken from patients at baseline, 2 hours after taking a 600-mg loading dose of clopidogrel, and 24 hours and 30 days after stenting. Platelet aggregation was measured by light transmittance aggregometry with adenosine diphosphate (5 and 20 μM) and arachidonic acid (500 and 5000 μg/mL). One hundred twelve patients were included (79 men, 33 women). Maximal and minimal clopidogrel nonresponsiveness occurred at 2 hours (26%) and 48 hours (13%) after taking 600 mg clopidogrel, respectively. Pretreatment platelet reactivity ha...

The Control of Hyperglycemia in Alloxan Treated Diabetic Mice through the Stimulation of Hepatic Insulin Synthesis due to the Production of Nitric Oxide

Experimental and Clinical Endocrinology and Diabetes — Mon, 09 Jan 2012 05:00:00 +0100

Exp Clin Endocrinol DiabetesDOI: 10.1055/s-0031-1291298The hepatocytes from the adult mice when stimulated by glucose had been reported to synthesize and secrete insulin. The feasibility of controlling hyperglycemia in alloxan induced diabetic mice through hepatic synthesis of insulin was studied.Insulin synthesis was determined by in vitro translation of mRNA and by immunohistochemistry of the hepatocytes and assayed by enzyme linked immunosorbent assay (ELISA). Dermcidin isoform 2 (dermcidin) was measured by ELISA. Nitric oxide was measured by methemoglobin method. Insulin synthesis was quantitated by immunoblot technique and the expression of proinsulin genes I and II in the hepatocytes was quantitated by cDNA synthesisIt was found that in contrast to normal hepatocytes, the hepatocytes...

Less Advanced Stages of Colon Cancer in Patients with Type 2 Diabetes Mellitus: an Unexpected Finding?

Experimental and Clinical Endocrinology and Diabetes — Mon, 09 Jan 2012 05:00:00 +0100

Exp Clin Endocrinol DiabetesDOI: 10.1055/s-0031-1299704Epidemiological studies have found an increased risk for colon cancer and faster disease progression in patients with type 2 diabetes mellitus (T2DM). We aimed to determine whether patients with T2DM are diagnosed with more advanced stages of colorectal cancer, i. e., metastasized disease (UICC III and IV), at the time of diagnosis, since such a finding may have an impact on future guidelines for patients with T2DM.A cross-sectional analysis of colorectal cancer patients was performed. Stages at diagnosis in patients with (18.0%) or without (82%) T2DM were compared using logistic regression analysis to correct for confounders.Patients with T2DM were older, more obese, and more often male (each p<0.05). Unexpectedly, patients with ...

Prescribed medicines for elderly frail people with diabetes resident in nursing homes - issues of polypharmacy and medication costs

NeLM - Care of Older People — Mon, 09 Jan 2012 05:00:00 +0100

Conclusions: Polypharmacy, defined as taking 4 or more drugs per day per resident, is highly prevalent within ... (Source: NeLM - Care of Older People)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Effects of inhaled nitric oxide on haemostasis in healthy adults treated with heparin: a randomized, controlled, blinded crossover study

Thrombosis Journal — Mon, 09 Jan 2012 05:00:00 +0100

Conclusions: Inhaled NO, when administered with heparin, exhibited no significant additive effects on ACT, PT, aPTT, bleeding time or platelet aggregation. (Source: Thrombosis Journal)

Effect of Aspirin on Vascular and Nonvascular Outcomes: Meta-analysis of Randomized Controlled Trials [Review Article]

Archives of Internal Medicine — Mon, 09 Jan 2012 05:00:00 +0100

Conclusions Despite important reductions in nonfatal MI, aspirin prophylaxis in people without prior CVD does not lead to reductions in either cardiovascular death or cancer mortality. Because the benefits are further offset by clinically important bleeding events, routine use of aspirin for primary prevention is not warranted and treatment decisions need to be considered on a case-by-case basis. (Source: Archives of Internal Medicine)

Aspirin Therapy in Primary Prevention: To Use or Not to Use?: Comment on "Effect of Aspirin on Vascular and Nonvascular Outcomes" [Invited Commentary]

Archives of Internal Medicine — Mon, 09 Jan 2012 05:00:00 +0100

(Source: Archives of Internal Medicine)

Low-Dose Aspirin to Prevent First Heart Attack or Stroke? Not So Fast

Cancercompass News: Other Cancer — Mon, 09 Jan 2012 00:00:00 +0100

Modest benefits might not outweigh bleeding risk, evidence review suggests (Source: Cancercompass News: Other Cancer)

Today in health: memory loss, aspirin and eyes

USATODAY.com Health — Fri, 06 Jan 2012 15:06:08 +0100

Memory loss can begin by age 45, daily aspirin is linked with an eye disease and a deep male voice may not mean what we think it means. (Source: USATODAY.com Health)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Could Daily Aspirin Harm Seniors' Eyes?

MedicineNet Cancer General — Fri, 06 Jan 2012 07:00:00 +0100

Title: Could Daily Aspirin Harm Seniors' Eyes?Category: Health NewsCreated: 1/5/2012 6:06:00 PMLast Editorial Review: 1/6/2012 (Source: MedicineNet Cancer General)